(Q78772835)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12521613%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

title

Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12521613%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

1 reference

1 reference

Jean-Pierre Sollet

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12521613%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Gary E Garber

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12521613%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

language of work or name

English

0 references

publication date

1 December 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12521613%20AND%20SRC:MED&resulttype=core&format=json

The American Journal of Surgery

16 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12521613%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

volume

184

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12521613%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

issue

6A Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12521613%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

page(s)

S11-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12521613%20AND%20SRC:MED&resulttype=core&format=json

Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment

16 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Efficacy and safety of recombinant human activated protein C for severe sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Antibiotic selection for patients with septic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Research in sepsis and acute respiratory distress syndrome: are we changing course?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Dear SIRS, I'm sorry to say that I don't like you

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Epidemiology of sepsis syndrome in 8 academic medical centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Reversal of late septic shock with supraphysiologic doses of hydrocortisone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Relation between respiratory changes in arterial pulse pressure and fluid responsiveness in septic patients with acute circulatory failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2802%2901132-7

10.1016/S0002-9610(02)01132-7

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12521613%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

1 reference